These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20069322)

  • 1. Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors.
    Jiang YK
    J Mol Model; 2010 Jul; 16(7):1239-49. PubMed ID: 20069322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CoMFA and CoMSIA of diverse pyrrolidine analogues as dipeptidyl peptidase IV inhibitors: active site requirements.
    Murugesan V; Sethi N; Prabhakar YS; Katti SB
    Mol Divers; 2011 May; 15(2):457-66. PubMed ID: 20737212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents.
    Saqib U; Siddiqi MI
    SAR QSAR Environ Res; 2009 Jul; 20(5-6):519-35. PubMed ID: 19916112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the structural requirements of triazole derivatives as promising DPP IV inhibitors: computational investigations.
    Shah BM; Sagar SR; Trivedi P
    J Biomol Struct Dyn; 2022; 40(24):13778-13798. PubMed ID: 34738504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR studies of Dipeptidyl peptidase IV inhibitors using a docking based alignment.
    Pissurlenkar RR; Shaikh MS; Coutinho EC
    J Mol Model; 2007 Oct; 13(10):1047-71. PubMed ID: 17676345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA.
    Zeng J; Liu G; Tang Y; Jiang H
    J Mol Model; 2007 Sep; 13(9):993-1000. PubMed ID: 17618469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors.
    Patel PD; Patel MR; Kaushik-Basu N; Talele TT
    J Chem Inf Model; 2008 Jan; 48(1):42-55. PubMed ID: 18076152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
    Musoev A; Numonov S; You Z; Gao H
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D QSAR and docking study of gliptin derivatives as DPP-IV inhibitors.
    Agrawal R; Jain P; Dikshit SN; Bahare RS
    Comb Chem High Throughput Screen; 2013 May; 16(4):249-73. PubMed ID: 23305140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.
    Liu Y; Si M; Tang L; Shangguan S; Wu H; Li J; Wu P; Ma X; Liu T; Hu Y
    Bioorg Med Chem; 2013 Sep; 21(18):5679-87. PubMed ID: 23938053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.
    Buolamwini JK; Assefa H
    J Med Chem; 2002 Feb; 45(4):841-52. PubMed ID: 11831895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docking-based 3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) study on hydroquinoline and thiazinan-4-one derivatives as selective COX-2 inhibitors.
    Dowlati Beirami A; Hajimahdi Z; Zarghi A
    J Biomol Struct Dyn; 2019 Jul; 37(11):2999-3006. PubMed ID: 30035675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR Studies on Barbituric Acid Derivatives as Urease Inhibitors and the Effect of Charges on the Quality of a Model.
    Ul-Haq Z; Ashraf S; Al-Majid AM; Barakat A
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27144563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.
    Liu Y; Wu Y; Wu H; Tang L; Wu P; Liu T; Hu Y
    Chem Biol Drug Des; 2013 Aug; 82(2):140-6. PubMed ID: 23530834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights of dipeptidyl peptidase-IV inhibitors through molecular dynamics-guided receptor-dependent 4D-QSAR studies.
    Patil RB; Barbosa EG; Sangshetti JN; Zambre VP; Sawant SD
    Mol Divers; 2018 Aug; 22(3):575-583. PubMed ID: 29536226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations of Structural Requirements for BRD4 Inhibitors through Ligand- and Structure-Based 3D QSAR Approaches.
    Tahir A; Alharthy RD; Naseem S; Mahmood N; Ahmed M; Shahzad K; Akhtar MN; Hameed A; Sadiq I; Nawaz H; Muddassar M
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29941841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CoMFA and CoMSIA 3D-QSAR analysis of DMDP derivatives as anti-cancer agents.
    Srivastava V; Kumar A; Mishra BN; Siddiqi MI
    Bioinformation; 2008 Jun; 2(9):384-91. PubMed ID: 18795111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid docking-QSAR studies of DPP-IV inhibition activities of a series of aminomethyl-piperidones.
    Amini Z; Fatemi MH; Gharaghani S
    Comput Biol Chem; 2016 Oct; 64():335-345. PubMed ID: 27570070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CoMFA and CoMSIA 3D-QSAR analysis of diaryloxy-methano-phenanthrene derivatives as anti-tubercular agents.
    Shagufta ; Kumar A; Panda G; Siddiqi MI
    J Mol Model; 2007 Jan; 13(1):99-109. PubMed ID: 16858589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.